Royalty Pharma plc
No SEC Form 4 filings for $RPRX in the last 30 days.
Royalty Pharma (RPRX) reported Q2 net income attributable to the company fell to $18 million from $32 million a year earlier. Adjusted EBITDA rose to $736 million from $633 million. Royalty Receipts grew 14% to $768 million, and Portfolio Receipts rose 6% to $773 million. The company raised 2026 Portfolio Receipts guidance to $3.400 billion to $3.500 billion.
Royalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rprx-20260630rpplcpressxre.htm EX-99.1 Document Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million
Royalty Pharma plc said it will appoint Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead outreach to academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. The company noted he previously worked at Memorial Sloan Kettering and AllianceBernstein.
Over the past 7 days, alphai's AI scored 3 news stories mentioning RPRX (Royalty Pharma plc). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent RPRX coverage spans mergers & acquisitions, earnings and sector analysis.
Guidance raise on 2026 Portfolio Receipts is the key fundamental catalyst, partially offset by lower reported net income.
Guidance raise plus strong Q2 royalty receipts growth supports near-term earnings power and may tighten valuation risk around cash flow durability.
Near-term impact is likely limited, but the hire signals continued emphasis on academic and translational partnerships.
Buying a royalty stream can improve RPRX’s cash-flow visibility, with valuation dependent on cliramitug sales trajectory.
Royalty Pharma will pay Neurimmune $125 million upfront for a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune will receive another $125 million in Q1 2027 and up to $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase III DepleTTR-CM, with results expected in 2028.
alphai scores every news story that mentions RPRX with an AI model for sentiment and relevance, and aggregates insider trades from Royalty Pharma plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Royalty Pharma (RPRX) reported Q2 net income attributable to the company fell to $18 million from $32 million a year earlier. Adjusted EBITDA rose to $736 million from $633 million. Royalty Receipts grew 14% to $768 million, and Portfolio Receipts rose 6% to $773 million. The company raised 2026 Portfolio Receipts guidance to $3.400 billion to $3.500 billion.
2 min readRoyalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rprx-20260630rpplcpressxre.htm EX-99.1 Document Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million
7 min readRoyalty Pharma plc said it will appoint Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead outreach to academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. The company noted he previously worked at Memorial Sloan Kettering and AllianceBernstein.
2 min readBiotech weekly roundup highlights EU approval for AstraZeneca’s Etcamah plus CDK4/6 inhibitors in ESR1-mutant ER+/HER2- advanced breast cancer, and accelerated FDA approval for GSK’s Jideytro in ROS1+ NSCLC. J&J received FDA De Novo for OTTAVA and reported Phase 3 PFS/OS gains for Talvey combos. Other items include deals (RGEN-BioLife, RPRX royalty buy) and trial updates for LLY, CLDX, and others.
7 min readRoyalty Pharma will pay Neurimmune $125 million upfront for a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune will receive another $125 million in Q1 2027 and up to $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase III DepleTTR-CM, with results expected in 2028.
5 min readRoyalty Pharma plc (RPRX) said it will acquire Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug for up to $425 million, according to the company. The deal covers a portion of the existing royalty interest tied to the drug.
2 min readRoyalty Pharma will buy part of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 cliramitug, in a deal worth up to $425 million. Royalty Pharma pays $125 million upfront, with $125 million in Q1 2027 plus up to $175 million tied to milestones. It receives 3% to 4% royalties on worldwide net sales. AstraZeneca expects Phase 3 results in 2028.
6 min readRoyalty Pharma said it acquired a royalty interest from Neurimmune tied to AstraZeneca’s cliramitug, a Phase 3 ATTR-CM drug. The deal totals up to $425M, including $125M upfront. Results are expected in 2028, and AstraZeneca projects peak sales of $3-5B, expanding Royalty Pharma’s royalty portfolio.
2 min readRoyalty Pharma (RPRX) said it will buy Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront. The deal grants RPRX a 3% to 4% royalty on worldwide net sales, with additional payments tied to milestones. Cliramitug is in Phase 3, with results expected in 2028.
4 min readDelveInsight reports systemic lupus erythematosus (SLE) remains incurable, with only GlaxoSmithKline’s Benlysta and AstraZeneca’s Saphnelo approved in the US. It cites a 2025 SLE market value of about $3B and forecasts 10.4% CAGR to 2036. The article highlights late-stage pipeline candidates including Biogen/Royalty Pharma’s litifilimab (Phase III readouts in 2H26) and Roche’s obinutuzumab (FDA decision expected by Dec 2026).
7 min read
